4D Molecular Therapeutics Inc
NASDAQ:FDMT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
4D Molecular Therapeutics Inc
NASDAQ:FDMT
|
US |
|
Shanghai International Airport Co Ltd
SSE:600009
|
CN |
4D Molecular Therapeutics Inc
4D Molecular Therapeutics is a gene therapy company that designs and develops treatments based on adeno-associated virus, or AAV, vectors. In simple terms, it tries to deliver working genes into cells to treat diseases at the source, rather than managing symptoms. Its main work is in diseases of the eye, heart, lungs, and other tissues where a one-time genetic treatment could be valuable. The company does not sell a broad portfolio of marketed drugs. It earns money through research-stage development, collaboration deals, and, if its programs succeed, future drug sales or licensing arrangements. Its customers today are mainly research partners, clinical trial sites, and eventually doctors, hospitals, and patients if any of its therapies win approval. What makes 4D Molecular Therapeutics different is its focus on engineering better viral delivery systems for gene therapy. That delivery step is the hard part in this field, because the gene has to reach the right cells safely and efficiently. The company is really selling a technical platform and a pipeline of drug candidates built on that platform, which puts it in the category of high-risk, long-development biotech rather than a traditional drug maker.
4D Molecular Therapeutics is a gene therapy company that designs and develops treatments based on adeno-associated virus, or AAV, vectors. In simple terms, it tries to deliver working genes into cells to treat diseases at the source, rather than managing symptoms. Its main work is in diseases of the eye, heart, lungs, and other tissues where a one-time genetic treatment could be valuable.
The company does not sell a broad portfolio of marketed drugs. It earns money through research-stage development, collaboration deals, and, if its programs succeed, future drug sales or licensing arrangements. Its customers today are mainly research partners, clinical trial sites, and eventually doctors, hospitals, and patients if any of its therapies win approval.
What makes 4D Molecular Therapeutics different is its focus on engineering better viral delivery systems for gene therapy. That delivery step is the hard part in this field, because the gene has to reach the right cells safely and efficiently. The company is really selling a technical platform and a pipeline of drug candidates built on that platform, which puts it in the category of high-risk, long-development biotech rather than a traditional drug maker.
